The location of reconnection at the magnetopause: Testing the maximum magnetic shear model with THEMIS observations [PDF]
K. J. Trattner +3 more
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Study on the Ratio and Model Test of Similar Materials of Heavily Weathered Granite. [PDF]
Hu G, Song W, Yu X, Lin M, Tie Y, He B.
europepmc +1 more source
Incremental testing of the community multiscale air quality (CMAQ) modeling system version 4.7
Kristen M. Foley +13 more
openalex +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Model test study on the mechanical response of the deep buried tunnel lining. [PDF]
Duan L, Feng J, Song J, Yao S.
europepmc +1 more source
A Model Test for the Influence of Lateral Pressure on Vertical Bearing Characteristics in Pile Jacking Process Based on Optical Sensors. [PDF]
Wang Y, Liu X, Sang S, Zhang M, Wang P.
europepmc +1 more source
A Toolchain for Model-based Design and Testing of Access Control Systems
Said Daoudagh +4 more
openalex +1 more source
Role Strains and Mood in Husbands of Women with Fibromyalgia Syndrome: A Test of the Stress Process Model [PDF]
Silvia M. Bigatti +2 more
openalex +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

